Treatments for Multiple Sclerosis: Effectiveness and Value

Draft Background and Scope

April 21, 2022

Background

Multiple sclerosis (MS) is a chronic, autoimmune disorder of the central nervous system (CNS) characterized by an inflammatory cascade of demyelination and axonal loss, which results in neurologic damage. The exact cause of MS is unknown, but genetic, environmental, and lifestyle factors may contribute to the development of the disease.[1] MS affects more than 900,000 people in the United States (US).[2] Women are affected almost 3 times more than men, and there are racial/ethnic differences in MS prevalence.[3] In the US, African Americans, particularly African American women, are at higher risk of developing MS compared with whites.[3,4] The total economic burden of MS is estimated to be $85 billion, with direct medical costs accounting for more than $63 billion.[5]

Symptoms of MS most commonly appear in the third decade of life, with symptoms correlating with areas of demyelination in the CNS. For example, demyelination of the optic nerve results in vision changes and eye pain (optic neuritis) and lesions in the spinal cord can lead to weakness, impaired sensation, and ataxia (partial myelitis).[1] Fatigue, pain, spasticity in muscles, balance problems, bowel and bladder dysfunction, insomnia, depression, and impaired memory and concentration are also possible symptoms.[6] Diagnosis of MS is based on the 2017 Revised McDonald Criteria, which involves a combination of clinical findings, imaging, and laboratory data, and requires the demonstration of MS disease characteristics in space (i.e., presence of lesions in distinct locations in the CNS) and time (development of new lesions over time).[7]

The most common form of MS is relapsing-remitting MS (RRMS), which affects 85% of persons and is characterized by periodic relapses with complete or near recovery. Disability accumulates over time with the median time for the need of a walking aid being approximately 20 years in untreated persons with MS (PwMS).[8] However, Black Americans with MS appear to have a more aggressive disease course, both with more severe initial symptoms and with faster disease progression.[9] Approximately 20% of persons with relapsing MS may develop progressive neurological decline and transition to secondary progressive MS (SPMS) around 15-20 years after diagnosis.[10] Life expectancy in PwMS is approximately 7 years shorter than average.[11]

Treatment of MS is focused on preventing relapses, disease progression, and worsening of disability. While supportive treatment, including symptom control, psychological support, management of comorbidities, lifestyle interventions, and rehabilitation, are important, primary treatment involves disease-modifying therapies (DMTs) that reduce neuroinflammation. There are multiple classes of DMTs with a variety of delivery mechanisms, efficacy, and risk of adverse events, including injections (interferons, glatiramer), oral medications (sphingosine 1-phosphate [S1P] receptor modulators, fumarates, teriflunomide), and intravenous or subcutaneous monoclonal antibodies. Choice of initial therapy is debatable, with some clinicians and PwMS opting to begin treatment with medications that have moderate efficacy but a better safety profile such as the injectable or oral drugs and escalating as needed; other clinicians and PwMS opt to treat with monoclonal antibodies at diagnosis, which have higher efficacy but a higher risk of serious adverse events. Treatment is generally lifelong, though DMT discontinuation may be considered in older, stable PwMS with non-active disease and low risk of progression.[12]

In addition to DMTs already approved by the Food and Drug Administration (FDA), there are additional agents in development, including ublituximab, a monoclonal antibody which is currently undergoing FDA review, and Bruton's tyrosine kinase inhibitors. Additionally, for some persons, hematopoietic stem cell transplantation (HSCT) has shown promise as a treatment for MS, though the ideal treatment population and optimal timing for HSCT have not yet been established.[13]

Stakeholder Input

This draft scoping document was developed with input from diverse stakeholders, including patient organizations, clinicians, researchers, and manufacturers of the agents of focus in this review. This document incorporates feedback gathered during preliminary calls with stakeholders and open input submissions from the public; we have also incorporated patient perspectives that were discussed during a prior 2017 ICER review of MS treatments. A revised scoping document will be posted following a three-week public comment period. ICER looks forward to continued engagement with stakeholders throughout its review and encourages comments to refine our understanding of the clinical effectiveness and value of preventive treatments.

Because the onset of MS is early in life, the disease has impact not only on the physical and emotional health of PwMS, but can also affect family planning, work and educational productivity, and social and leisure activities. Economic hardship, including lost wages from missed work, the need to transition to part-time work, the inability to continue working, and the high cost of medications and medical equipment, is a major burden for PwMS.[14] There can also be impact on caregivers, particularly with progression of patient disability, and caregivers can experience high levels of distress and decreased quality of life.[15]

The primary goal for PwMS is to remain independent, including the ability to continue working and perform normal activities. Although ambulation is an important marker of disability, debilitating

fatigue and cognitive changes also have a great impact on one's daily life activities, particularly on the ability to work. Thus, early diagnosis and treatment are critical to making the impact of MS on a person's life as minimal as possible. The most important issues for PwMS when considering treatment are how well a DMT delays onset of disability and prevents relapses or new MRI lesions, whether a treatment is oral or otherwise, and the risks for adverse events, particularly for serious adverse events that might accompany the higher efficacy therapies.[14] Additionally, the high cost of DMTs – even generic formulations – can lead to large out-of-pocket costs, and burden of prior authorization can also affect patient choice for therapy.

Neurologists agreed that the main goal of treatment for MS is to prevent or delay progression of disability and noted that the choice of starting with moderate or high efficacy DMT is dependent on patient characteristics as well as patient and clinician preferences. Clinical trials such as TREAT-MS (NCT03500328) and DELIVER-MS (NCT03535298) are currently in progress to help ascertain what the best treatment strategies for MS treatment are. Additionally, clinical experts mentioned that there is both under- and over-treatment of the disease. For example, some patients would benefit from being treated with more aggressive therapies (i.e., under treatment); on other hand, older patients with non-MS-related life-limiting conditions continue to be treated despite not having active disease (i.e., over treatment). Furthermore, clinicians advised that the Expanded Disability Status Scale (EDSS), the current standard for measuring disability in clinical trials, may not be optimal for measuring all aspects of disability and quality of life for PwMS, particularly cognitive function.

Manufacturers noted some challenges in interpreting clinical trials, including the changing criteria for diagnosis and the changing standard of care over time, as well as the difficulty in identifying persons who have transitioned from RRMS to SPMS.

Report Aim

This project will evaluate the health and economic outcomes of oral agents (fumarates, S1P receptor modulators, teriflunomide) and monoclonal antibody treatments (intravenous and subcutaneous) for relapsing forms of MS. The ICER value framework includes both quantitative and qualitative comparisons across treatments to ensure that the full range of benefits and harms – including those not typically captured in the clinical evidence such as innovation, public health effects, reduction in disparities, and unmet medical needs – are considered in the judgments about the clinical and economic value of the interventions.

Scope of Clinical Evidence Review

The proposed scope for this assessment is described on the following pages using the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. Evidence will

be abstracted from randomized controlled trials as well as high-quality systematic reviews; high-quality comparative cohort studies will be considered, particularly for long-term outcomes and uncommon adverse events. Our evidence review will include input from PwMS and patient advocacy organizations, data from regulatory documents, information submitted by manufacturers, and other grey literature when the evidence meets ICER standards (for more information, see ICER's grey literature policy).

All relevant evidence will be synthesized qualitatively or quantitatively. Wherever possible, we will seek out head-to-head studies of the interventions and comparators of interest. Data permitting, we will also consider combined use of direct and indirect evidence in network meta-analyses of selected outcomes. Full details regarding the literature search, screening strategy, data extraction, and evidence synthesis will be provided after the revised scope in a research protocol published on the Open Science Framework website (https://osf.io/7awvd/).

Populations

The population of focus for the review is adults with relapsing forms of MS, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS).

Data permitting, we intend to examine the following subgroups including, but not limited to:

1. Race/ethnicity
2. Age
3. Pregnant or planning a pregnancy
4. CIS subgroup
5. RRMS subgroup
6. Active SPMS subgroup
7. No previous use of disease-modifying therapy/treatment naïve

Interventions and Comparators

We intend to compare agents within the monoclonal antibodies class to one another as well as against leading oral therapies using head-to-head and placebo-controlled trials. We also plan to compare all the agents to one another though network meta-analysis. We note that rituximab does not include an FDA label for persons with relapsing forms of multiple sclerosis. However, given past and ongoing randomized MS trials that include rituximab[16,17], observational data that suggest efficacy of rituximab[18,19], and hearing from clinical experts, we decided to keep rituximab within the scope of our assessment.

The full list of interventions is as follows:

- Monoclonal antibodies
    - natalizumab (Tysabri®, Biogen)
    - ofatumumab (Kesimpta®, Novartis)
    - ocrelizumab (Ocrevus®, Genentech)
    - rituximab (Rituxan®, Genentech, and biosimilars)
    - ublituximab (TG Therapeutics)
- Oral therapies
    - Fumarates:
        - dimethyl fumarate (Tecfidera®, Biogen, and generics)
        - diroximel fumarate (Vumerity®, Biogen)
        - monomethyl fumarate (Bafiertam®, Banner Life Sciences)
    - S1P receptor modulators:
        - fingolimod (Gilenya®, Novartis)
        - ozanimod (Zeposia®, Bristol Myers Squibb)
        - ponesimod (Ponvory®, Janssen)
        - siponimod (Mayzent®, Novartis)
    - teriflunomide (Aubagio®, Sanofi)

Outcomes

The outcomes of interest are described in the list below.

- Patient-important outcomes
    - Disability improvement or progression as measured by
        - Expanded Disability Status Scale (EDSS)
        - Multiple Sclerosis Functional Composite measure (MSFC)
    - Relapse
    - Cognitive function
    - Fatigue
    - Depression
    - Manual dexterity
    - Visual acuity
    - Health-related quality of life outcomes
    - Need for caretaker/health aide
    - Treatment adherence
    - Ability to maintain employment
    - Adverse events including
        - Serious adverse events (SAEs)

- Adverse events (AEs) leading to discontinuation of therapy
- AEs unique to specific drugs
- Other Outcomes
  - Magnetic resonance imaging (MRI) outcomes (T2, T1, brain volume changes)
  - No evidence of disease activity (NEDA 3 and/or 4)
  - Caregiver impact
    - Caregiver quality of life
    - Caregiver health
    - Caregiver productivity

Timing

Evidence on intervention effectiveness will be derived from studies of at least one year's duration and evidence on harms from studies of at least three month's duration.

Settings

All relevant settings will be considered, with a focus on outpatient settings in the United States.

Potential Other Benefits and Contextual Considerations

Our reviews seek to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that would not have been considered as part of the evidence on comparative clinical effectiveness. These general elements (i.e., not specific to a given disease) are listed in the table below.

Table 1.1. Categories of Contextual Considerations and Potential Other Benefits or Disadvantages

Contextual Consideration*
Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
Magnitude of the lifetime impact on individual patients of the condition being treated
Other (as relevant)

*Contextual considerations refer to social or ethical priorities that shape to some extent how the value of any effective treatments for a particular condition will be judged.

Potential Other Benefit or Disadvantage*
Patients' ability to achieve major life goals related to education, work, or family life
Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
Patients' ability to manage and sustain treatment given the complexity of regimen
Society's goal of reducing health inequities
Other (as relevant)

*Potential other benefits or disadvantages are meant to reflect the broader effects of a specific treatment on patients, caregivers, and society.

ICER encourages stakeholders to provide input on these elements in their public comment submissions.

Scope of Comparative Value Analyses

As a complement to the evidence review, we will develop an economic model to assess the lifetime cost effectiveness of treatment initiation of monoclonal antibodies, including at least ofatumumab and ublituximab, as compared to treatment initiation of market leading oral therapies, including at least dimethyl fumarate and fingolimod. The model structure will be based in part on a literature review of prior published models of relapsing forms of MS, including models developed for prior ICER reviews related to MS.[14,20-24] The base-case analysis will take a health care sector perspective (i.e., focus on direct medical care costs only). Data permitting, productivity impacts and other indirect costs will be considered in a separate analysis. This modified societal perspective analysis will be considered as a co-base case when the societal costs of care are large relative to direct health care costs, and the impact of treatment on these costs is substantial. This will most often occur in cases where the incremental cost-effectiveness ratio changes by greater than 20%, greater than $200,000 per quality-adjusted life years (QALY), and/or when the result crosses the threshold of $100,000-$150,000 per QALY gained.

The target population will consist of adults ages 18 years and older in the US with relapsing forms of MS. The model will consist of health states defined by EDSS and death. A cohort of patients will transition between these health states during predetermined cycles of one year over a lifetime time horizon, modeling patients from treatment initiation until death. If a patient discontinues the initial therapy, they will transition to a subsequent DMT treatment basket with an annual cost representative of the average cost of a market basket of DMTs and treatment effectiveness equivalent to the least effective of the modeled therapies. Key model inputs will include clinical probabilities, quality of life values, and health care costs. Probabilities, costs, and other inputs will differ to reflect varying effectiveness between interventions. Treatment effectiveness, measured by annualized relapse rates (ARR) and disability progression, will be estimated using planned network meta-analysis.

Health outcomes will be dependent on time spent in each health state (defined by EDSS category), clinical events, and AEs. The health outcome of each intervention will be evaluated in terms of the number of relapses, life-years (LY), QALYs, and equal value of life years (evLY). Quality of life weights will be applied to each health state, including quality of life decrements for serious adverse events. The model will include direct medical costs, including but not limited to costs related to drug administration, drug monitoring, condition-related care, and serious adverse events. In addition, productivity changes and other indirect costs will be included in a separate analysis if available data allow. All future costs and consequences will be discounted at 3% per year. Results

will be expressed in terms of the marginal cost per QALY gained, cost per evLY gained, cost per LY gained, and cost per relapse averted.

In separate analyses, we will explore the potential health care system budgetary impact of ublituximab over a five-year time horizon, utilizing published or otherwise publicly available information on the potential population eligible for ublituximab and results from the economic model for treatment costs and cost offsets. This budgetary impact analysis will indicate the relation between treatment prices and level of use for a given potential budget impact and will allow assessment of any need for managing the cost of such interventions. More information on ICER's methods for estimating potential budget impact can be found here.

Identification of Low-Value Services

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create additional resources in health care budgets for higher-value innovative services (for more information, see ICER's Value Assessment Framework). These services are ones that would not be directly affected by treatments for MS (e.g., cost of nursing care or physical therapy), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of MS beyond the potential offsets that arise from a new intervention. ICER encourages all stakeholders to suggest services (including treatments and mechanisms of care) that could be reduced, eliminated, or made more efficient.

References

1.   McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. *Jama.* 2021;325(8):765-779.
2.   Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. *Neurology.* 2019;92(10):e1029-e1040.
3.   Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. *Brain.* 2012;135(Pt 6):1778-1785.
4.   Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. *Neurology.* 2013;80(19):1734-1739.
5.   Bebo B, Cintina I, LaRocca N, et al. Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs. *Neurology.* 2022.
6.   Olek MJ. Multiple Sclerosis. *Ann Intern Med.* 2021;174(6):ITC81-ITC96.
7.   Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018;17(2):162-173.
8.   Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. *N Engl J Med.* 2000;343(20):1430-1438.
9.   Cipriani VP, Klein S. Clinical Characteristics of Multiple Sclerosis in African-Americans. *Curr Neurol Neurosci Rep.* 2019;19(11):87.
10. University of California SFMSET, Cree BA, Gourraud PA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. *Ann Neurol.* 2016;80(4):499-510.
11. Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. *Neurology.* 2015;85(3):240-247.
12. McFaul D, Hakopian NN, Smith JB, Nielsen AS, Langer-Gould A. Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. *Neurol Neuroimmunol Neuroinflamm.* 2021;8(2).
13. Miller AE, Chitnis T, Cohen BA, et al. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. *JAMA Neurol.* 2021;78(2):241-246.
14. Tice J, Chapman, R, Kumar, V, Loos, AM, Liu, S, Seidner, M, Ollendorf, DA, Rind, D, Pearson SD. Disease-Modifying Therapies for RelapsingRemitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value - Final Evidence Report. https://icer.org/wp-content/uploads/2020/10/CTAF_MS_Final_Report_030617.pdf. Published 2017. Accessed April 7, 2022.
15. Giordano A, Cimino V, Campanella A, et al. Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. *J Neurol Sci.* 2016;366:139-145.
16. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med.* 2008;358(7):676-688.
17. Ontaneda D, Tallantyre EC, Raza PC, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. *Contemp Clin Trials.* 2020;95:106009.
18. Granqvist M, Boremalm M, Poorghobad A, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. *JAMA Neurol.* 2018;75(3):320-327.
19. Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. *Neurology.* 2016;87(20):2074-2081.

20.   Sharaf R, Synnott, P, Chapman, R, Samur, S, Adair, E, Rind, D, Pearson S. Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value - Final Evidence Report. https://icer.org/wp-content/uploads/2020/10/ICER_MS_Final_Evidence_Report_062019.pdf. Published 2019. Accessed April 7, 2022.

21.   Zimmermann M, Brouwer E, Tice JA, et al. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. *CNS Drugs.* 2018;32(12):1145-1157.

22.   Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.* 2009;12(5):657-665.

23.   Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. *J Med Econ.* 2016;19(4):432-442.

24.   National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing–remitting multiple sclerosis. Final appraisal determination. https://www.nice.org.uk/guidance/ta320/documents/multiple-sclerosis-relapsingremitting-dimethyl-fumarate-final-appraisal-determination-document2. Published 2014. Accessed April 7, 2022.